YDES
What one share of YD Bio Limited holds
Services – Medical Laboratories
We are a publicly listed biotechnology company focused on regulated diagnostics, life science clinical services, and healthcare product commercialization. Our operations include DNA methylation-based oncology testing programs in the United States conducted under a LDT framework in collaboration with CLIA-certified and CAP-accredited laboratory partners.
YD Bio Limited’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $0.01 |
|---|---|
| Profit | −$0.12 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$0.12 |
| Cash and investments | $0.08 |
| Debt | $0.00 |
| Book value | −$0.04 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $0.01 | $0.00 | $0.00 | −$0.00 | — | — |
| 2024 | $0.01 | −$0.02 | $0.00 | −$0.02 | — | $0.10 |
| 2025 | $0.01 | −$0.12 | $0.02 | −$0.12 | — | −$0.04 |